Arcus Biosciences, Inc. (NYSE:RCUS) Receives $34.00 Average PT from Analysts

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have received a consensus rating of “Buy” from the nine analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $34.00.

A number of equities analysts have recently commented on RCUS shares. Wedbush reiterated an “outperform” rating and set a $36.00 price target on shares of Arcus Biosciences in a report on Thursday, November 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcus Biosciences in a report on Thursday, October 3rd. Barclays increased their price target on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. Wells Fargo & Company assumed coverage on Arcus Biosciences in a research note on Tuesday, October 8th. They issued an “overweight” rating and a $29.00 price objective on the stock. Finally, HC Wainwright reissued a “neutral” rating and set a $20.00 target price on shares of Arcus Biosciences in a research report on Wednesday, November 6th.

Institutional Trading of Arcus Biosciences

Hedge funds have recently modified their holdings of the stock. Louisiana State Employees Retirement System grew its holdings in Arcus Biosciences by 2.6% in the second quarter. Louisiana State Employees Retirement System now owns 27,500 shares of the company’s stock worth $419,000 after purchasing an additional 700 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Arcus Biosciences by 2.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,781 shares of the company’s stock valued at $471,000 after buying an additional 843 shares during the period. JPMorgan Chase & Co. increased its position in Arcus Biosciences by 2.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 43,685 shares of the company’s stock valued at $668,000 after buying an additional 1,117 shares in the last quarter. WINTON GROUP Ltd increased its position in Arcus Biosciences by 3.3% in the 2nd quarter. WINTON GROUP Ltd now owns 59,137 shares of the company’s stock valued at $901,000 after buying an additional 1,872 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Arcus Biosciences by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 58,173 shares of the company’s stock worth $886,000 after acquiring an additional 1,951 shares in the last quarter. Institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Price Performance

Shares of RCUS opened at $15.13 on Friday. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. The stock has a market cap of $1.38 billion, a PE ratio of -4.80 and a beta of 0.88. Arcus Biosciences has a 12-month low of $13.52 and a 12-month high of $20.31. The business has a 50-day simple moving average of $15.94 and a two-hundred day simple moving average of $16.02.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.06. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The company had revenue of $48.00 million during the quarter, compared to the consensus estimate of $38.95 million. During the same quarter in the prior year, the firm posted ($0.94) earnings per share. The firm’s revenue was up 50.0% compared to the same quarter last year. Analysts anticipate that Arcus Biosciences will post -3.2 earnings per share for the current fiscal year.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.